You just read:

New England Journal of Medicine Publishes Two Positive Phase 3 Trials Showing DUPIXENT® (dupilumab) Improved Moderate-to-Severe Asthma

News provided by

Regeneron Pharmaceuticals, Inc.

May 21, 2018, 02:14 ET